EU: Agreed Medicines Directive Text Published, Repealing 2001/83/EC

On September 17, 2026, the European Parliament published document PE792.228, the agreed interinstitutional compromise text for the EU Directive on the Union code relating to medicinal products for human use, procedure 2023/0132(COD) (PDF, SANT committee). The text, which will repeal Directive 2001/83/EC and Directive 2009/35/EC, now appears in the Legislative Observatory documentation gateway ahead of the indicative plenary sitting of October 19, 2026.

The publication does not change the law yet. It gives marketing authorisation holders the actual settled text to analyze. The substantive compromise was reached at trilogue on December 11, 2025, endorsed by COREPER on March 6, 2026, and approved by the Parliament's Committee on Public Health (SANT) on March 18, 2026. PE792.228 is the formal write-up of that compromise, the reference every regulatory affairs team will work from until the final act is published in the Official Journal.

What does the agreed directive settle for marketing authorisation holders?

The directive rewrites the Union code that Directive 2001/83/EC has governed since 2001, covering definitions, marketing authorisation requirements, manufacturing, distribution, pharmacovigilance, and advertising. It is one of two instruments in the pharmaceutical package, negotiated and agreed with the Council as a single compromise: the directive (2023/0132(COD)) sets the Union code, while the companion Regulation (2023/0131(COD)) replaces Regulation (EC) No 726/2004 and covers the centralised procedure, the European Medicines Agency, and incentives. Reading PE792.228 means reading one half of a negotiated whole.

Within that package, a marketing authorisation becomes valid for an unlimited period by default, ending the routine five-year renewal. The EMA's human medicines committees are consolidated from five to two, leaving the Committee for Medicinal Products for Human Use (CHMP) for benefit-risk assessment and the Pharmacovigilance Risk Assessment Committee (PRAC) for safety monitoring. Scientific assessment tightens from 210 to 180 days, and the Commission decision step from 67 to 46 days, shortening the path from application to authorisation.

Which incentives and obligations change under the package?

The negotiated package resets the EU incentives map. Baseline regulatory data protection is set at eight years, modulated upward for products addressing unmet medical need and capped at eleven years. Orphan market exclusivity runs up to eleven years. A transferable data exclusivity voucher is introduced for developers of new antimicrobials, an incentive with no equivalent in the current framework and a direct answer to the antimicrobial resistance pressure the recitals flag.

Set against those rewards, marketing authorisation holders face a mandatory shortage-prevention plan obligation, tying the directive to the supply-security logic of the parallel Critical Medicines Act. The net effect redraws EU launch strategy: longer protection for innovative medicines that address unmet need or reach patients across the Union, paired with tighter duties on continuity of supply.

What is the legislative path from this agreed text to entry into force?

PE792.228 is the agreed text, not the adopted act. Under Rule 75(4) of the Parliament's Rules of Procedure, the SANT committee submits the provisional agreement for decision by a single vote, and the plenary is scheduled to vote on October 19, 2026. After plenary adoption, the Council must adopt the same text, followed by legal-linguistic revision and signature by the Presidents of both institutions. The directive is then published in the Official Journal and enters into force the twentieth day after publication.

Because this is a directive, not a regulation, it is not directly applicable: each Member State must transpose it into national law before the transposition deadline the act itself will fix. Full applicability across the EU is foreseen from 2028. The Legislative Observatory procedure file tracks each of these steps as they land.

Subscribe to the free newsletter

Regulatory affairs teams should now read PE792.228 against their EU launch portfolios. Confirm which products gain or lose data protection under the modulated scheme, map the shortage-prevention plan duty to current supply-chain governance, and track the October 19 plenary for any last-minute amendment. Because the directive requires transposition, flag the national implementation milestones in every Member State where you hold an authorisation. Continuous per-jurisdiction monitoring surfaces each of these milestones the moment it publishes, so the next step never arrives unannounced.